Translational studies revealed that DCAF1 blocked the 4G2 antibody with high efficacy and inhibited the ADE process during DENV infection in a cell line model, whereas DCAF4 relieved the disease symptoms by complement cascade inhibition and MAC reduction in a passive transfer myasthenia gravis rat model. The gene discussed is DCAF1; the disease is myasthenia gravis.